Product Information
CARBAMAZEPINE ER 300 MG CAP is a generic product labeled by AvPAK, priced at $1.0746 per EA under NDC 50268017213. Its NADAC has been published 223 times since Jun 29, 2022.
FDA first approved this application on Nov 25, 2011. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Carbamazepine market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
300 mg/1
Manufacturer
AvPAKNDC
50268017213
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CARBAMAZEPINEApproval Type
Generic (ANDA)
FDA Application
ANDA078986FDA Approved
11/25/2011
TE Code
AB
On Market Since
10/19/2021
Pharmacological Classes
Price Statistics
The NADAC for CARBAMAZEPINE ER 300 MG CAP has been published 223 times since Jun 29, 2022, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.0746 per EA |
|---|---|
| All-time high | $1.2690 (Dec 13, 2023) |
| All-time low | $0.7413 (Jul 17, 2024) |
| 52-week high | $1.1200 |
| 52-week low | $1.0113 |
| Median price | $1.0742 |
| Average price | $1.0467 |
| Largest weekly change | -31.3% (Nov 20, 2024) |
| Weeks tracked | 223 |
| Tracking since | Jun 29, 2022 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
AvPAK manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Carbamazepine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Mood Stabilizer class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CARBAMAZEPINE ER 300 MG CAP?
The current National Average Drug Acquisition Cost (NADAC) for CARBAMAZEPINE ER 300 MG CAP, manufactured by AvPAK, is $1.0746 per EA (NDC 50268017213), effective Sep 30, 2026.
How has the price of CARBAMAZEPINE ER 300 MG CAP changed over time?
Over the history we have for it, the NADAC for CARBAMAZEPINE ER 300 MG CAP has held within roughly two percent of its current level. It has been tracked across 223 weekly CMS publications since Jun 29, 2022.
What are the highest and lowest recorded NADAC prices for CARBAMAZEPINE ER 300 MG CAP?
Since Jun 29, 2022, the NADAC for CARBAMAZEPINE ER 300 MG CAP has ranged from a low of $0.7413 (Jul 17, 2024) to a high of $1.2690 (Dec 13, 2023), with a median of $1.0742 per EA.
Are there cheaper alternatives to CARBAMAZEPINE ER 300 MG CAP?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as CARBAMAZEPINE ER 300 MG CAP in a comparable dosage form, but none are currently priced below it.
Who manufactures CARBAMAZEPINE ER 300 MG CAP?
CARBAMAZEPINE ER 300 MG CAP (NDC 50268017213) is labeled by AvPAK, and CMS classifies it as a generic product.